Anderson–Darling test

From WikiMD's WELLNESSPEDIA


The Anderson–Darling test is a statistical test used to determine if a given sample of data is drawn from a specified probability distribution. Developed by Theodore W. Anderson and Donald A. Darling in 1952, the test is a modification of the Cramér–von Mises criterion and is used extensively in statistics for hypothesis testing.

Overview[edit]

The Anderson–Darling test is particularly sensitive to deviations in the tail ends (extreme values) of the distribution. This sensitivity makes it more effective than other tests, such as the Kolmogorov–Smirnov test, for detecting differences in the tails of the distributions. The test is applicable to a variety of distributions including the normal distribution, exponential distribution, Weibull distribution, and others.

Methodology[edit]

The test statistic, A², is calculated by: \[ A^2 = -n - \frac{1}{n} \sum_{i=1}^n (2i - 1) \left[ \ln(F(Y_i)) + \ln(1 - F(Y_{n+1-i})) \right] \] where:

  • \( n \) is the sample size,
  • \( Y_i \) are the sorted data points,
  • \( F \) is the cumulative distribution function of the specified theoretical distribution.

The null hypothesis \( H_0 \) of the Anderson–Darling test states that the data follow the specified distribution. Rejection of the null hypothesis indicates that the data do not follow the distribution.

Applications[edit]

The Anderson–Darling test is widely used in quality control, reliability engineering, and other fields that require robust assessment of distribution fit. It is particularly useful in the context of parametric statistical inference, where the form of the distribution might significantly influence conclusions.

Limitations[edit]

While the Anderson–Darling test is powerful for detecting departures from a specified distribution, it can be overly sensitive to sample size. Large samples might lead to rejection of the null hypothesis for trivial deviations that are of no practical significance. Additionally, the test requires that the parameters of the distribution be fully specified; if parameters are estimated from the data, the critical values of the test statistic change, complicating its application.

See also[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.